Rheumatoid Arthritis

ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD #RNL2026 https://t.co/LidiS3Wj9d

Links:

Dr. John Cush @RheumNow( View Tweet )
Advanced Practice Rheum: Methotrexate In this session, we're going to review methotrexate. It is the most popular of disease-modifying drugs used in rheumatology. While it may be indicated for a few disorders, it's widely used in many inflammatory and autoimmune disorders. https://t.co/RKh3mQv7Hx
Dr. John Cush @RheumNow( View Tweet )
Cancer.risk_.jpg

Malignancies Not Increased with Biologic Therapies

Jack Cush, MD

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo

Read Article
ILD in RA - Recent Advances. Dr. Jeffrey Sparks ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD https://t.co/0AWneSEPjP

Links:

Dr. John Cush @RheumNow( View Tweet )
Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/mre5aQcR8M

Links:

Dr. John Cush @RheumNow( View Tweet )
Korean Insurance claims nested case–control study of 27,410 RA pts - 5482 w/ > comorbid Dsx Vs 21,928 w/ < 10 comorbd Dz. Having >10 signif incr Serious infx (OR 1.44), opportunistic (21.9)& Hzoster (1.18); mainly skin & soft tissue infx - NOT fatal infx. https://t.co/qDrU3BXYzd
Dr. John Cush @RheumNow( View Tweet )
Korean study 50600 adult RA pts (Dx 2010-2020) shows Sustained high-income was assoc w/ reduced mortality, esp in younger pts (adj HR 0.50 <65 years vs 0.74 ≥65 years). Amplifed by Rural residence https://t.co/DUZoNsPSHj https://t.co/PV3Umlrgvv

Links:

Dr. John Cush @RheumNow( View Tweet )
ILD in RA - Recent Advances. Dr. Jeffrey Sparks ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/R3hWpqxo8q #Rheumatology #ILD https://t.co/XsA6hiiTrd

Links:

Dr. John Cush @RheumNow( View Tweet )
Open label RCT in 116 DMARD-naïve #RA pts Rx w/ tofacitinib or MTX (after 1 IM steroid injx). @3 mos, TOFA signif better than MTX for >50% SDAI improv(94 v 75%), CDAI[14.5 v 7.3), DAS28-CRP[1.7 v 1.2] https://t.co/smOuLlVFyX https://t.co/xGvbiu62OB

Links:

Dr. John Cush @RheumNow( View Tweet )
Japanese ANSWER study Rx 7268 RA pts initiating bDMARDs or JAKi by orthos or Rheums. Vs Rheums, Ortho Rx RA had longer Dz duration, more seropositivity, functional impairment, less comorbidity, more MTX/GC/TNFi, less AE D/Cs - responses & outcomes were similar https://t.co/1ryA8C2p1b
Dr. John Cush @RheumNow( View Tweet )
What's it like to have RA? MARY: "I can manage the pain, the exhaustion, and side effects of the meds. The hard part is grief. I grieve for me, the adventurer that decided what she wanted and boldly went after it, no matter what. I trusted myself to handle whatever came. Now https://t.co/GakWIy2XCt
Dr. John Cush @RheumNow( View Tweet )
Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/c9IVwQYwMN
Dr. John Cush @RheumNow( View Tweet )
What's it like to have RA? LISA: "It only took me three short years to go from rock climbing to a power wheel chair and that stage of the disease was frightening and painful and you feel hopeless and as if your life plan is being stolen from you. Once I was able to start https://t.co/d49htc8k4m
Dr. John Cush @RheumNow( View Tweet )
What's it like to have #RA? RICHARD: "There were days that I couldn’t mask the pain or hide the limp..So I tried to deny and hide the disease. I would always go up and down stairs when no one was looking. I got up extra early so no one could see me walk like an old man to the https://t.co/krHn4yoRYd
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

What’s New PsA? (4.3.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

Read Article
Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UbEoBz37hT https://t.co/V9WzfRtbFQ

Links:

Dr. John Cush @RheumNow( View Tweet )
What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp
Dr. John Cush @RheumNow( View Tweet )
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and its implications. 🎧 Listen here: https://t.co/QxldIpYQC8 #Rheumatology #Autoimmunity #RNL2026 https://t.co/nz2dbwll14

Links:

Dr. John Cush @RheumNow( View Tweet )
ILD.colors

Review: Rheumatoid Arthritis–Associated Interstitial Lung Disease

Jack Cush, MD

RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe. Prevalence estimates vary widely  (up to 58%), reflecting different diagnostic criteria, imaging modalities, and study

Read Article
Italian population study of 37996 RA (prevalence 0.54%) pts w/ and 12875 incident cases (incid rate 33.1/100K), there were 1288 deaths/8yrs (MR 21.3/1K), median age=83; SMR 1.28 (1.21 to 1.35), higher <45 yrs (2.15). Leading causes CV (37%), cancer (21%) & infxn (11%) https://t.co/wPx5iqW7Nl
Dr. John Cush @RheumNow( View Tweet )
Time to pregnancy (TTP) in 2 RA cohorts: PARA (n 245, 2002-10) vs PreCARA (n 215, 2011-23), latter Rx by T2T. Median TTP was 251d vs 91d (p<0·0001). Preg w/in 1 yrs was 42% v 77%. 61% PreCARA in remission https://t.co/qIHwXvfzMy https://t.co/1huBKiarhH

Links:

Dr. John Cush @RheumNow( View Tweet )
Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/2ZVyf8neVH
Dr. John Cush @RheumNow( View Tweet )
Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UlBuUhtB01 https://t.co/09OEk1OLs2

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Moral Distress (3.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.  This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

Read Article
Incident RA is assoc w/ considerable work loss. 3850 RA pts compared to 4422 same-sex siblings (2006-2020). Work loss began 13 mos before RA Dx & peaked the year after, less in last 10 yrs. Work loss highly skewed; small proportion contributed the most work loss days. https://t.co/splolrEDpe
Dr. John Cush @RheumNow( View Tweet )

Therapeutic Updates

A JAKi CHAT: Shared Decision-Making in RA

AbbVie October
Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.
Read Post

Recent Blogs

Advanced Practice Rheum

Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD
D2T RA Cover
Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).
Read Article
Advanced Practice Rheum

Methotrexate

Jack Cush, MD
APR MTX Cover
In this session, Dr. Jack Cush reviews methotrexate.
Read Article
Advanced Practice Rheum

Rheumatoid & Inflammation Testing

Jack Cush, MD
APR Rheum and Inflammation Testing Cover
Master the dos and don'ts of ordering RF, CCP (ACPA), and inflammatory markers that could transform your diagnostic accuracy.
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 RA Topic Podcasts Compilation 6
  • ACR 2025 Daily Podcasts Day4b
  • ACR 2025 RA Topic Podcasts Compilation 5
×